Cargando…

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer

BACKGROUND: In patients with advanced non-small cell lung cancer (aNSCLC), cemiplimab plus chemotherapy prolonged overall survival (OS) and progression-free survival (PFS) significantly compared to chemotherapy alone. The cost-effectiveness of these drugs is still uncertain. The aim of this study is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Xueyan, Chen, Xiaoyu, Li, Huijuan, Li, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171429/ https://www.ncbi.nlm.nih.gov/pubmed/37182130 http://dx.doi.org/10.3389/fonc.2023.1113374

Ejemplares similares

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
por: Liang, Xueyan, et al.
Publicado: (2023)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
por: Lu, Tingting, et al.
Publicado: (2023)

Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis
por: Li, Yan, et al.
Publicado: (2022)

Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis
por: Zhu, Gaofeng, et al.
Publicado: (2023)

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
por: Gogishvili, Miranda, et al.
Publicado: (2022)

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Yang, Szu-Chun, et al.
Publicado: (2021)

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
por: Chen, Ting, et al.
Publicado: (2022)

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China
por: Zhang, Mengdie, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
por: Hu, Huabin, et al.
Publicado: (2020)

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer
por: Feliciano, Josephine Louella, et al.
Publicado: (2023)

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study
por: Fang, Xiaoxu, et al.
Publicado: (2023)

Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified
por: Chen, Zegeng, et al.
Publicado: (2021)

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
por: Wang, Hao, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
por: Huo, Gengwei, et al.
Publicado: (2023)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
por: Tang, Ning, et al.
Publicado: (2016)

First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study
por: Wu, Yahua, et al.
Publicado: (2023)

Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
por: Xu, J. L., et al.
Publicado: (2015)

Best Supportive Care Versus Whole-Brain Irradiation, Chemotherapy Alone, or WBRT Plus Chemotherapy in Patients With Brain Metastases From Small-Cell Lung Cancer: A Case-Controlled Analysis
por: Li, Hongwei, et al.
Publicado: (2021)

Surgery Plus Chemotherapy Versus Surgery Alone for Limited-Stage Small-Cell Lung Cancer: A Population-Based Survival Outcome Analysis
por: Ye, Pingting, et al.
Publicado: (2021)

Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China
por: Shu, Yamin, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
por: Zeng, Hao, et al.
Publicado: (2021)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

The Clinical Outcomes and Toxicities of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Zou, Rui, et al.
Publicado: (2021)

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
por: Jian, Hong, et al.
Publicado: (2017)

Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer
por: Zhao, Lingdi, et al.
Publicado: (2020)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer
por: Wen, Feng, et al.
Publicado: (2018)

A prognostic model for predicting progression-free survival in patients with advanced non-small cell lung cancer after image-guided microwave ablation plus chemotherapy
por: Kong, Fanhao, et al.
Publicado: (2023)

Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis
por: Qiu, Lupeng, et al.
Publicado: (2022)

Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Li, Lingling, et al.
Publicado: (2021)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression
por: Zhang, Chuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3n3oubj513olqcqeprv688qfam